HAYWARD, Calif., Aug. 31 /PRNewswire-FirstCall/ -- Cholestech Corporation , a leading manufacturer of point of care testing devices, today announced that Warren E. Pinckert II, President and CEO, and Jack Glenn, CFO, will present at the Roth Capital Partners' 2006 New York Investor Conference on Thursday, September 7, 2006, at 10:00 a.m. Eastern Time in New York City, New York. The presentation will include an overview of the company, current products, product pipeline and recent financial performance; and will be webcast and accessible on Cholestech's website at http://www.cholestech.com/ .
About Cholestech
Cholestech is committed to enabling people to lead longer, healthier and more active lives. Cholestech provides easy to use, accessible diagnostic tools and information to health care practitioners in over 35 countries around the world. Cholestech offers efficient and economic diagnostic testing for cholesterol and related lipids, blood glucose and glycemic control, and liver enzymes at the point of care. Health care providers can use the CLIA-waived Cholestech LDX(R) and GDX(TM) Systems and the hs-CRP test, which is cleared by the FDA for use in moderate complexity labs, to initiate and monitor the progress of patient therapy. By providing effective disease management solutions, Cholestech's goal is to be a leading provider of diagnostic tools and information for immediate risk assessment and therapeutic monitoring of heart disease and diabetes.
Cholestech LDX(R) is a registered trademark and Cholestech GDX(TM) is a trademark of Cholestech Corporation. All other trademarks mentioned in this document are the property of their respective owners. For more information about Cholestech and its products visit us on the web at http://www.cholestech.com/ .
